Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the prevalence and severity of CAD (coronary artery disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular risk factors.
To establish the relationship between psoriasis and coronary disease by comparing the prevalence and severity of CAD (coronary artery disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular risk factors, as determined by CT coronary calcium scoring and Coronary CT angiography.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjects with severe psoriasis | Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan. |
| |
| Subjects without psoriasis | Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CCTA Scan (Coronary CT Angiogram) | Procedure | CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD). |
|
| Measure | Description | Time Frame |
|---|---|---|
| To establish the relationship between psoriasis and coronary disease | 1 year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Prior diagnosis of CAD (coronary artery disease) or heart disease based upon one or more of the following:
History of anti-oxidants such as fish oil or biologic therapy Tumor Necrosis Factor alpha inhibitors (such as etanercept, adalimumab, or infliximab). A recent review by Sattar et al [22] has shown preliminary evidence that TNF (tumor necrosis factor) blockade can modulate nontraditional cardiovascular risk factors such as C-reactive protein(CRP), Interleukin-6(IL-6), Apolipoprotein AI(ApoAI), Lipoprotein(a)(Lp[a]), Sex Hormone Binding Globulin (SHBG), and homocysteine to exert a possible vascular and metabolic protective effect.
Pustular and erythrogenic psoriasis
Unable to give informed consent
Contraindications to coronary CT, including:
Not provided
Not provided
Subjects with severe psoriasis will be selected prospectively from the clinics of the University of Michigan, Dept. of Dermatology.
The comparison group (subjects without psoriasis) will be targeted in the Dermatology clinic by screening for matching variables before enrollment. This group will be matched by age and gender to the psoriasis population, and on Framingham risk score.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Prachi P Agarwal, M.D. | University of Michigan Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| D003324 | Coronary Artery Disease |
| D001172 | Arthritis, Rheumatoid |
| D001168 | Arthritis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D003327 | Coronary Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
31 ml of blood will be drawn in conjunction with this study.Lipid, Glucose and Lipoprotein will be drawn in one SST tube = 7 ml. Insulin (INS) will be collected in one Green top tube = 7 ml. HSCRP- will be collected in on SSS tube = 7 ml. IL-6 will be collected in Red or Lavender top tube = 7 ml. An additional 3 ml will be drawn for ICAM testing. (The blood for the ICAM testing and IL- 6 will be drawn and frozen until funding has been obtained to run these tests). Specimens will be be properly disposed of after testing is completed.
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |